Cancer stem cells: targeting tumors at the source

被引:0
作者
Zhang, P. -Y. [1 ]
Yang, Y. -J. [2 ]
Xue, Y. [2 ]
Fu, J. [2 ]
Zhang, C. -X. [2 ]
Wang, Y. [2 ]
Yang, Y. [2 ]
Shi, H. [2 ]
机构
[1] Xuzhou Cent Hosp, Ctr Canc, Dept Hematol, Xuzhou, Jiangsu, Peoples R China
[2] Xuzhou Cent Hosp, Dept Hematol, Xuzhou, Jiangsu, Peoples R China
关键词
Cancer stem cell (CSC); Self-renewal; Differentiation; progenitor; Wnt-beta-catenin; Notch; Hedgehog; BRCA1; Clonal origin; Niche environment; PHILADELPHIA-CHROMOSOME; MYELOID-LEUKEMIA; MUTATIONS; ONCOGENE; QUIESCENCE; NOTCH1; LUNG; TRANSFORMATION; MECHANISMS; PROGENITOR;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cancer stem cell hypothesis states that tumors rely exclusively on the continued proliferation of a subset of cancer cells that originated from normal adult stem cells. These cells have two key traits: multipotency, and self-renewal. The prolonged lifespan of stem cells makes them perfect candidates for the accumulation of carcinogenic mutations that would convert them into cancer stem cells (CSCs) no longer responsive to the many regulatory pathways in place that are responsible for tight governance of proliferation and differentiation in normal stem cells. Comprehending what these regulatory pathways are, and how their derailment contributes to oncogenic transformation, can hold the key to finding new strategies to target CSCs in order to effectively treat cancer. Additionally, what environmental factors are involved in promoting or suppressing CSC tumorigenicity requires attention. The possibility that some cancers may have clonal origins in non-stem cell populations that were able to acquire stem cell-like properties, and the lack of complete cell autonomy in carcinogenesis, suggests that the CSC hypothesis is continually evolving. Continued research in this field can shed light on how effective selective elimination of CSCs as opposed to generalized targeting of cancer cells will be in the treatment of cancer.
引用
收藏
页码:1821 / 1828
页数:8
相关论文
共 55 条
[1]   In vivo analysis of quiescent adult neural stem cells responding to Sonic hedgehog [J].
Ahn, S ;
Joyner, AL .
NATURE, 2005, 437 (7060) :894-897
[2]  
Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24
[3]  
American Cancer Society, 2014, EARL HIST CANC
[4]   Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche [J].
Arai, F ;
Hirao, A ;
Ohmura, M ;
Sato, H ;
Matsuoka, S ;
Takubo, K ;
Ito, K ;
Koh, GY ;
Suda, T .
CELL, 2004, 118 (02) :149-161
[5]   BRCA1 Suppresses Epithelial-to-Mesenchymal Transition and Stem Cell Dedifferentiation during Mammary and Tumor Development [J].
Bai, Feng ;
Chan, Ho Lam ;
Scott, Alexandria ;
Smith, Matthew D. ;
Fan, Cheng ;
Herschkowitz, Jason I. ;
Perou, Charles M. ;
Livingstone, Alan S. ;
Robbins, David J. ;
Capobianco, Anthony J. ;
Pei, Xin-Hai .
CANCER RESEARCH, 2014, 74 (21) :6161-6172
[6]   3 CLONAL TYPES OF KERATINOCYTE WITH DIFFERENT CAPACITIES FOR MULTIPLICATION [J].
BARRANDON, Y ;
GREEN, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (08) :2302-2306
[7]   Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation [J].
Bhardwaj, G ;
Murdoch, B ;
Wu, D ;
Baker, DP ;
Williams, KP ;
Chadwick, K ;
Ling, LE ;
Karanu, FN ;
Bhatia, M .
NATURE IMMUNOLOGY, 2001, 2 (02) :172-180
[8]   An APC: NT counter-current-like mechanism regulates cell division along the human colonic crypt axis: a mechanism that explains how APC mutations induce proliferative abnormalities that drive colon cancer development [J].
Boman, Bruce M. ;
Fields, Jeremy Z. .
FRONTIERS IN ONCOLOGY, 2013, 3
[9]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[10]   Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells [J].
Brummendorf, TH ;
Dragowska, W ;
Zijlmans, JMJM ;
Thornbury, G ;
Lansdorp, PM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (06) :1117-1124